Home › About ›
PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, welcomes Dr. Ellen Baron as a member of the Company’s Board of Directors following its recent initial public offering.
Dr. Ellen Baron has been a Managing Director at Outcome Capital LLC, a specialized life science and technology strategic advisory and investment banking firm, since February 2017, serving as global head of the Biopharmaceutical practice. From 2012-2017, she served as a Managing Director of Healthios Capital Markets, LLC. Before joining Healthios, Dr. Baron served as Lifescience Venture Capital Partner at Oxford Bioscience Partners and as Senior Vice President, Business Development at Human Genome Sciences, a publicly traded biopharmaceutical company. Dr. Baron previously spent 20 years at Schering-Plough Corporation in both research and development, as well as business development. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a biotech company, Sixth Element Capital, UK-based oncology focused venture capital fund, and SFH, a Maine-based nutraceutical company. Dr. Baron holds a Ph.D. in Microbiology from Georgetown University School of Medicine, a post-doctorate at the Public Health Research Institute in New York and a bachelor’s degree from Goucher College.
Dr. Ehud Geller, Chairman of the Board, commented, “I am pleased to welcome Dr. Ellen Baron to our board, as she brings extensive experience and a successful track record in both the healthcare industry and capital markets. Ellen has proven value as a strategic advisor with exceptional business acumen and interpersonal skills, deep healthcare industry expertise and relationships, and financial acumen. She has been instrumental in financing life science companies and has deep domain expertise across multiple disciplines in the pharmaceutical and biotechnology industries. In addition, her clinical expertise and background in business development will be important as we advance our planned Phase 3 trial, plan our commercialization activities and seek out potential strategic partners. We remain highly encouraged by the outlook for the business and look forward to her contributions as we execute on our mission to bring PRF-110 to market, which we believe has the potential to become standard of care within the multi-billion dollar post-operative pain market.”